Mitochondrial liquid-liquid phase separation in Alzheimer's disease
Funded at Yeshiva University · NIH-11592219 · Data updated 2026-11-12
A small NIH grant aims to understand how the Alzheimer’s-linked toxin Aβ42 affects mitochondrial function in cells, with the hope of guiding future treatments.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yeshiva University NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | January 1, 2025 |
| Project end | June 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $151,475 |
| NIH project number | 7R03AG087431-02 |
| Project ID | NIH-11592219 on NIH RePORTER |
Who could benefit from this research
✓Could help
This research is at the basic mechanism level in cell models and does not require patient participation at this stage.
✕Less likely to help
Direct patient participation is not required for this basic cell-model study.
What this research studies
In this project, researchers study how Alzheimer's disease–related Aβ42 affects mitochondria, the powerhouses of the cell. They focus on a specific mechanism called liquid-liquid phase separation inside mitochondria and how it might lead to mitochondrial problems. Using basic cell models, they will examine how Aβ42 changes mitochondrial RNA-protein granules and test ways to control these processes with light-based tools. The goal is to uncover mechanism-based ideas that could someday lead to new therapeutic strategies for Alzheimer’s disease.
Why it matters
Potential benefit: If successful, the work could reveal new targets for therapies that protect mitochondria and slow Alzheimer's progression.
How similar studies have gone: Other studies have linked mitochondrial dysfunction and Aβ42 to Alzheimer’s, with some evidence that subcellular organelle dynamics influence disease progression.
Where this research is happening
-
Yeshiva University
New York, United States Active
Researchers
- Principal investigator: Kim, Nam Chul — Yeshiva University
- Study coordinator: Kim, Nam Chul
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.